Table 1.
Selected trials currently enrolling patients for AML featuring targeted agents.
| Agents | Investigation | Phase | Identifier |
|---|---|---|---|
| Gemtuzumab Ozogamicin | Liposome-encapsulated daunorubicin-cytarabine and GO in treating patients with r/r AML or high-risk MDS | 1 | NCT03672539 |
| Fractionated GO in treating MRD measurable residual disease in participants with AML | 2 | NCT03737955 | |
| Sorafenib | Sorafenib + busulfan and fludarabine conditioning in r/r AML undergoing stem cell transplantation | 1/2 | NCT03247088 |
| Sorafenib plus azacitidine in AML/MDS patients with FLT3-ITD mutation | 2 | NCT02196857 | |
| Midostaurin | Midostaurin + chemotherapy in newly diagnosed FLT3-WT AML | 3 | NCT03512197 |
| Crenolanib vs. midostaurin following induction chemotherapy and consolidation therapy in newly diagnosed FLT3 mutant AML | 3 | NCT03258931 | |
| Quizartinib | Quizartinib with standard of care chemotherapy and as continuation therapy in new diagnosed FLT3-ITD AML | 3 | NCT02668653 |
| Quizartinib and venetoclax in r/r FLT3 mutated AML | 1b/2 | NCT03735875 | |
| Crenolanib | Crenolanib combined with chemotherapy in r/r FLT3 mutated AML | 1b/2 | NCT02298166 |
| Crenolanib maintenance following allogeneic stem cell transplantation in FLT3-mutant AML | 2 | NCT02400255 | |
| Gilteritinib | Gilteritinib vs. midostaurin in FLT3 mutant AML during induction and consolidation chemotherapy | 2 | NCT03836209 |
| Gilteritinib as maintenance therapy following induction/consolidation therapy in FLT3-ITD AML in 1.CR | 3 | NCT02927262 | |
| Enasidenib/Ivosidenib | Ivosidenib or Enasidenib combined with induction/consolidation, followed by maintenance therapy in IDH1/IDH2 mutated AML/MDS2-EB2 | 3 | NCT03839771 |
| Enasidenib vs. conventional care regimens in IDH2 mutant elderly AML | 3 | NCT02577406 | |
| Ivosidenib vs. placebo in combination with azacitidine in IDH1 mutant AML | 3 | NCT03173248 | |
| Glasdegib | Intensive chemotherapy +/− glasdegib or azacitidine +/− glasdegib AML patients | 3 | NCT03416179 |
| Immunotherapy combinations for AML for example, glasdegib plus avelumab | 1b/2 | NCT03390296 | |
| Venetoclax | Venetoclax combined with gilteritinib in r/r AML | I | NCT03625505 |
| Venetoclax +/− azacitidine in AML, ineligible for intensive treatment | 3 | NCT02993523 | |
| Venetoclax +/− low dose cytarabine in AML, ineligible for intensive treatment | 3 | NCT03069352 | |
| Venetoclax combined with induction/consolidation chemotherapy in AML | 1b | NCT03709758 |